BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 23150997)

  • 1. Response assessment in Waldenström macroglobulinaemia: update from the VIth International Workshop.
    Owen RG; Kyle RA; Stone MJ; Rawstron AC; Leblond V; Merlini G; Garcia-Sanz R; Ocio EM; Morra E; Morel P; Anderson KC; Patterson CJ; Munshi NC; Tedeschi A; Joshua DE; Kastritis E; Terpos E; Ghobrial IM; Leleu X; Gertz MA; Ansell SM; Morice WG; Kimby E; Treon SP;
    Br J Haematol; 2013 Jan; 160(2):171-6. PubMed ID: 23150997
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of serum immunoglobulin free light chain in response and progression in waldenstrom macroglobulinemia.
    Leleu X; Xie W; Bagshaw M; Banwait R; Leduc R; Roper N; Weller E; Ghobrial IM
    Clin Cancer Res; 2011 May; 17(9):3013-8. PubMed ID: 21415221
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Uniform response criteria in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia.
    Weber D; Treon SP; Emmanouilides C; Branagan AR; Byrd JC; Bladé J; Kimby E
    Semin Oncol; 2003 Apr; 30(2):127-31. PubMed ID: 12720121
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bortezomib as a treatment option in patients with Waldenström macroglobulinemia.
    Dimopoulos MA; Chen C; Kastritis E; Gavriatopoulou M; Treon SP
    Clin Lymphoma Myeloma Leuk; 2010 Apr; 10(2):110-7. PubMed ID: 20371443
    [TBL] [Abstract][Full Text] [Related]  

  • 5. IgMκ and IgMλ Measurements for the Assessment of Patients with Waldenström's Macroglobulinaemia.
    Boyle E; Manier S; Lejeune J; Fouquet G; Guidez S; Bonnet S; Debarri H; Demarquette H; Dulery R; Gay J; Hennache B; Onraed B; Faucompré JL; Schraen S; Facon T; Avet-Loiseau H; Chevret S; Leblond V; Harding S; Leleu X
    Clin Cancer Res; 2016 Oct; 22(20):5152-5158. PubMed ID: 27169996
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multicenter clinical trial of bortezomib in relapsed/refractory Waldenstrom's macroglobulinemia: results of WMCTG Trial 03-248.
    Treon SP; Hunter ZR; Matous J; Joyce RM; Mannion B; Advani R; Cook D; Songer J; Hill J; Kaden BR; Sharon D; Steiss R; Leleu X; Branagan AR; Badros A
    Clin Cancer Res; 2007 Jun; 13(11):3320-5. PubMed ID: 17545538
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bortezomib is active in patients with untreated or relapsed Waldenstrom's macroglobulinemia: a phase II study of the National Cancer Institute of Canada Clinical Trials Group.
    Chen CI; Kouroukis CT; White D; Voralia M; Stadtmauer E; Stewart AK; Wright JJ; Powers J; Walsh W; Eisenhauer E;
    J Clin Oncol; 2007 Apr; 25(12):1570-5. PubMed ID: 17353550
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Pathology, diagnostics, and treatment of Waldenström's macroglobulinaemia].
    Holmström MO
    Ugeskr Laeger; 2011 Oct; 173(41):2557-60. PubMed ID: 21985832
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Monoclonal IgM interference with immunoturbidimetric determination of transferrin].
    Boniol C; Tournilhac O; Kuder P; Guyon M; Dastugue B; Motta C; Sapin V
    Ann Biol Clin (Paris); 2002; 60(4):481-4. PubMed ID: 12147455
    [No Abstract]   [Full Text] [Related]  

  • 10. Bone-marrow plasma cell burden correlates with IgM paraprotein concentration in Waldenstrom macroglobulinaemia.
    Pasricha SR; Juneja SK; Westerman DA; Came NA
    J Clin Pathol; 2011 Jun; 64(6):520-3. PubMed ID: 21471142
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Monoclonal IgM interference with immunoturbidimetric determination of ferritin and transferrin].
    Roszyk L; Faye B; Tournilhac O; Fogli A; Sapin V
    Ann Biol Clin (Paris); 2007; 65(6):659-62. PubMed ID: 18039612
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Appropriateness of applying the response criteria for multiple myeloma to Waldenstrom's macroglobulinemia?
    Bladé J; Montoto S; Rosiñol L; Montserrat E
    Semin Oncol; 2003 Apr; 30(2):329-31. PubMed ID: 12720163
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Attainment of complete/very good partial response following rituximab-based therapy is an important determinant to progression-free survival, and is impacted by polymorphisms in FCGR3A in Waldenstrom macroglobulinaemia.
    Treon SP; Yang G; Hanzis C; Ioakimidis L; Verselis SJ; Fox EA; Xu L; Hunter ZR; Tseng H; Manning RJ; Patterson CJ; Sheehy P; Turnbull B
    Br J Haematol; 2011 Jul; 154(2):223-8. PubMed ID: 21564078
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Update on recommendations for assessing response from the Third International Workshop on Waldenstrom's Macroglobulinemia.
    Kimby E; Treon SP; Anagnostopoulos A; Dimopoulos M; Garcia-Sanz R; Gertz MA; Johnson S; LeBlond V; Fermand JP; Maloney DG; Merlini G; Morel P; Morra E; Nichols G; Ocio EM; Owen R; Stone M; Bladé J
    Clin Lymphoma Myeloma; 2006 Mar; 6(5):380-3. PubMed ID: 16640813
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative response assessment by serum immunoglobulin M M-protein and total serum immunoglobulin M after treatment of patients with Waldenström macroglobulinemia.
    Tripsas CK; Patterson CJ; Uljon SN; Lindeman NI; Turnbull B; Treon SP
    Clin Lymphoma Myeloma Leuk; 2013 Apr; 13(2):250-2. PubMed ID: 23664027
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Waldenström macroglobulinemia: 2013 update on diagnosis, risk stratification, and management.
    Gertz MA
    Am J Hematol; 2013 Aug; 88(8):703-11. PubMed ID: 23784973
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Maintenance Rituximab is associated with improved clinical outcome in rituximab naïve patients with Waldenstrom Macroglobulinaemia who respond to a rituximab-containing regimen.
    Treon SP; Hanzis C; Manning RJ; Ioakimidis L; Patterson CJ; Hunter ZR; Sheehy P; Turnbull B
    Br J Haematol; 2011 Aug; 154(3):357-62. PubMed ID: 21615385
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Initial immunoglobulin M 'flare' after rituximab therapy in patients diagnosed with Waldenstrom macroglobulinemia: an Eastern Cooperative Oncology Group Study.
    Ghobrial IM; Fonseca R; Greipp PR; Blood E; Rue M; Vesole DH; Gertz MA;
    Cancer; 2004 Dec; 101(11):2593-8. PubMed ID: 15493038
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Effective treatment with rituximab in two patients with Waldenström macroglobulinemia].
    Yoshimi A; Arai S; Iijima K; Iki S; Usuki K; Urabe A
    Rinsho Ketsueki; 2005 Oct; 46(10):1109-13. PubMed ID: 16440772
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A review of Waldenstrom's macroglobulinemia.
    McDermott MK; Bell EM
    Clin J Oncol Nurs; 1999 Jul; 3(3):107-11. PubMed ID: 10690041
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.